Self-expanding versus balloon expanding coronary stents in intervention of the degenerated saphenous vein graft

• Verfasst von: Siry, Marcus [VerfasserIn]
• Verfasst von: Duymaz, Burak [VerfasserIn]
• Verfasst von: Biesenberger, Simon [VerfasserIn]
• Verfasst von: Siry, Deborah [VerfasserIn]
• Verfasst von: Kammerer, Vanessa [VerfasserIn]
• Verfasst von: May, Andreas E. [VerfasserIn]
• Titel: Self-expanding versus balloon expanding coronary stents in intervention of the degenerated saphenous vein graft
• Titelzusatz: Memmingen Coronary Artery Bypass Stenosis Trial (MECAST)
• Verf.angabe: Marcus Siry, Burak Duymaz, Simon Biesenberger, Deborah Siry, Vanessa Kammerer, and Andreas E. May
• E-Jahr: 2023
• Jahr: 06 Apr 2023
• Umfang: 10 S.
• Fussnoten: Gesehen am 16.05.2023
• Titel Quelle: Enthalten in: Journal of interventional cardiology
• Ort Quelle: London : Hindawi, 1988
• Jahr Quelle: 2023
• Band/Heft Quelle: 2023(2023) vom: Apr., Artikel-ID e9412132, Seite 1-10
• ISSN Quelle: 1540-8183
• DOI: doi:10.1155/2023/9412132
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1845509951

Abstract

Objectives. The aim of this retrospective analysis was to compare the patient outcome after interventional therapy of saphenous vein graft (SVG) stenoses in an all-comers population receiving either self-expanding drug-eluting stents (SExS) or balloon expanding drug-eluting stents (BExS). Background. The interventional therapy of degenerated SVGs remains challenging. Diameter variations of stenotic segments and friable plaques can lead to malapposition and distal embolization with increased major adverse cardiac event (MACE) rates. Methods. 107 patients with a total of 130 SVG interventions were separated into two groups according to either SExS (n = 51) or BExS (n = 56) treatment. Primary endpoint was the MACE rate, which is defined as the composite of cardiac death, myocardial infarction (MI), target vessel (TVR), and target lesion revascularization (TLR) at 30 days and at one-year follow-up. Results. Both patient groups did not differ significantly regarding patient characteristics. The patient outcome was significantly better in the SExS patient group: the MACE rate at 30 days was 1/51 (2.0%) in group SExS vs. 7/56 (12.5%) in group BExS; . At one-year follow-up, the MACE rate remained significantly lower in the SExS group 8/51(15.7%) vs. 20/56 (35.7%) in the BExS group, . Additionally, cardiac death occurred significantly later within the SExS patient group compared to the BExS group (). A better overall outcome of patients with de novo SVG-stenosis compared to patients with previous CABG (coronary artery bypass graft) intervention was noted in both groups. Conclusion. Our findings demonstrate that SVG treatment with SExS is safe and provides clinical benefits by comparatively improving short and especially long-term patient outcomes.